- Home
- LCFY vs AIDX Comparison
LCFY vs AIDX Comparison
Compare LCFY & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCFY | AIDX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 6.7M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LCFY | AIDX |
|---|---|---|
| Price | $2.35 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 63.4K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.48 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,045,133.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $2.10 | $0.40 |
| 52 Week High | $7.75 | $14.09 |
Technical Indicators
Market Signals| Indicator | LCFY | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 38.79 |
| Support Level | $2.28 | $0.40 |
| Resistance Level | $2.65 | $0.49 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 40.01 | 8.64 |
Price Performance
Historical ComparisonAbout LCFY Locafy Limited
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.